Sheng Yong Yang
Overview
Explore the profile of Sheng Yong Yang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen S, Yang S, Zeng X, Zhu F, Tan Y, Jiang Y, et al.
Drug Dev Res
. 2020 Sep;
82(1):133-142.
PMID: 32931039
Cancers resist targeted therapeutics by drug-escape signaling. Multitarget drugs co-targeting cancer and drug-escape mediators (DEMs) are clinically advantageous. DEM coverage may be expanded by drug combinations. This work evaluated to...
2.
Chen S, Yang S, Chen Z, Tan Y, Jiang Y, Chen Y
Drug Dev Res
. 2018 Nov;
80(2):246-252.
PMID: 30422335
The clinical advantage of co-targeting cancer drug escape has been indicated by the percentage of these co-targeting drugs among all multi-target drugs in clinics and clinical trials. This clinical advantage...
3.
Zhu F, Li X, Yang S, Chen Y
Trends Pharmacol Sci
. 2018 Jan;
39(3):229-231.
PMID: 29295742
The selection of the right drug targets is critically important for the successful and cost-effective development and clinical testing of drugs. A 2009 paper reported an in silico prospective prediction...
4.
Zeng X, Tao L, Zhang P, Qin C, Chen S, He W, et al.
Bioinformatics
. 2017 May;
33(20):3276-3282.
PMID: 28549078
Motivation: Genetic and gene expression variations within and between populations and across geographical regions have substantial effects on the biological phenotypes, diseases, and therapeutic response. The development of precision medicines...
5.
Chen S, Zhang P, Liu X, Qin C, Tao L, Zhang C, et al.
J Mol Graph Model
. 2016 Jun;
67:102-10.
PMID: 27262528
The overall efficacy and safety profile of a new drug is partially evaluated by the therapeutic index in clinical studies and by the protective index (PI) in preclinical studies. In-silico...
6.
Zhang C, Tao L, Qin C, Zhang P, Chen S, Zeng X, et al.
Nucleic Acids Res
. 2014 Nov;
43(Database issue):D558-65.
PMID: 25414339
Similarity-based clustering and classification of compounds enable the search of drug leads and the structural and chemogenomic studies for facilitating chemical, biomedical, agricultural, material and other industrial applications. A database...
7.
Qin C, Zhang C, Zhu F, Xu F, Chen S, Zhang P, et al.
Nucleic Acids Res
. 2013 Nov;
42(Database issue):D1118-23.
PMID: 24265219
Here we describe an update of the Therapeutic Target Database (http://bidd.nus.edu.sg/group/ttd/ttd.asp) for better serving the bench-to-clinic communities and for enabling more convenient data access, processing and exchange. Extensive efforts from...
8.
Liu X, Shi Z, Xue Y, Rong Li Z, Yang S, Wei Y, et al.
Curr Drug Saf
. 2012 Sep;
7(3):225-37.
PMID: 22950377
Drug adverse effects (ADEs) and toxicities have been extensively studied from chemical structure, genetic, biological systems and clinical perspectives. The rapid accumulation of chemical, biological and clinical data are highly...
9.
Kumar P, Ma X, Liu X, Jia J, Bucong H, Xue Y, et al.
J Comput Aided Mol Des
. 2011 May;
25(5):455-67.
PMID: 21556903
Various in vitro and in-silico methods have been used for drug genotoxicity tests, which show limited genotoxicity (GT+) and non-genotoxicity (GT-) identification rates. New methods and combinatorial approaches have been...
10.
Ma X, Wang R, Xue Y, Rong Li Z, Yang S, Wei Y, et al.
Curr Drug Saf
. 2008 Aug;
3(2):100-14.
PMID: 18690988
As part of the intensive efforts in facilitating drug discovery, computational methods have been explored as low-cost and efficient tools for predicting various toxicological properties and adverse drug reactions (ADR)...